Placebo to DFV890 10 mg and 25 mg film-coated tablet clinical trials

A randomized, placebo-controlled, parallel-group, investigator- and participant-blinded Phase 2a study to investigate the efficacy, safety, and tolerability of DFV890 and MAS825 for inflammatory marker reduction in an adult population with coronary heart disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

This study is testing new medicines, DFV890 and MAS825, for adults with heart disease and a blood condition called CHIP. We want to see if these medicines can lower inflammation and if they are safe. Some people will get a dummy treatment (placebo) for comparison.